This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

开始日期2024-05-01

申办/合作机构

Arrowhead Pharmaceuticals, Inc.

NCT06347133 / Recruiting临床3期

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.

开始日期2024-05-01

申办/合作机构

Arrowhead Pharmaceuticals, Inc.

NCT06347003 / Recruiting临床3期

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

开始日期2024-05-01

申办/合作机构

Arrowhead Pharmaceuticals, Inc.

100 项与 Plozasiran 相关的临床结果

登录后查看更多信息

100 项与 Plozasiran 相关的转化医学

登录后查看更多信息

100 项与 Plozasiran 相关的专利（医药）

登录后查看更多信息

项与 Plozasiran 相关的文献（医药）

2023-11-28·NEJM Evidence

Randomized Phase I Trials — One Size Fits All?

作者: Halabi, Susan ; Chiuzan, Codruta

In this issue of NEJM Evidence, Gaudet et al. present the safety profile and pharmacodynamics of ARO-APOC3, a small interfering RNA therapeutic that inhibits apolipoprotein C-III (APOC3) mRNA expression in a phase I trial.¹ Assignment to treatment was based on fasting levels of triglycerides. The trial included two double-blinded cohorts with 52 randomly assigned healthy participants and 40 patients with hypertriglyceridemia assigned to escalating doses of ARO-APOC3 at 10, 25, 50, or 100 mg or placebo in a single- and/or repeat-dose (days 1 and 29) regimen. An open-label cohort of patients with chylomicronemia was treated with ARO-APOC3 at 50 mg.

2023-11-28·NEJM Evidence

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia

Article

作者: Melquist, Stacey ; Gaudet, Daniel ; San Martin, Javier ; Watts, Gerald F. ; Scott, Russell ; Schwabe, Christian ; Hegele, Robert A. ; Zhou, Rong ; Clifton, Peter ; Knowles, Joshua W. ; Sullivan, David ; Hamilton, James ; Thackwray, Susan ; Given, Bruce ; Goldberg, Ira J. ; Ballantyne, Christie M. ; Chang, Ting ; Baker, John

APOC3-Targeting RNAi for HypertriglyceridemiaThis randomized controlled trial examined the safety and side effects of the small interfering RNA ARO-APOC3 in healthy volunteers and patients with hypertriglyceridemia and chylomicronemia. ARO-APOC3 was associated with few adverse events and no dose-limiting toxicities.

2023-11-01·Current atherosclerosis reports

Updates in Small Interfering RNA for the Treatment of Dyslipidemias.

Review

作者: Sirtori, C R ; Carugo, S ; Tokgozoglu, L ; Gelpi, G ; Corsini, A ; Ruscica, M

PURPOSE OF REVIEW:

Atherosclerotic cardiovascular disease (ASCVD) is still the leading cause of death worldwide. Despite excellent pharmacological approaches, clinical registries consistently show that many people with dyslipidemia do not achieve optimal management, and many of them are treated with low-intensity lipid-lowering therapies. Beyond the well-known association between low-density lipoprotein cholesterol (LDL-C) and cardiovascular prevention, the atherogenicity of lipoprotein(a) and the impact of triglyceride (TG)-rich lipoproteins cannot be overlooked. Within this landscape, the use of RNA-based therapies can help the treatment of difficult to target lipid disorders.

RECENT FINDINGS:

The safety and efficacy of LDL-C lowering with the siRNA inclisiran has been documented in the open-label ORION-3 trial, with a follow-up of 4 years. While the outcome trial is pending, a pooled analysis of ORION-9, ORION-10, and ORION-11 has shown the potential of inclisiran to reduce composite major adverse cardiovascular events. Concerning lipoprotein(a), data of OCEAN(a)-DOSE trial with olpasiran show a dose-dependent drop in lipoprotein(a) levels with an optimal pharmacodynamic profile when administered every 12 weeks. Concerning TG lowering, although ARO-APOC3 and ARO-ANG3 are effective to lower apolipoprotein(apo)C-III and angiopoietin-like 3 (ANGPTL3) levels, these drugs are still in their infancy. In the era moving toward a personalized risk management, the use of siRNA represents a blossoming armamentarium to tackle dyslipidaemias for ASCVD risk reduction.

项与 Plozasiran 相关的新闻（医药）

2024-05-02

·BioSpace

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate development, regulatory, and sales milestone payments associated with olpasiran. “The rapid enrollment of the OCEAN(a) - Outcomes Trial demonstrates the strong interest in olpasiran, developed using Arrowhead’s proprietary TRiMTM technology and licensed to Amgen in 2016. Partnering is an important part of our strategy and we are pleased with all the care and work undertaken to bring this potentially important new therapy closer to patients,” said Christopher Anzalone, Ph.D., Arrowhead’s president and CEO. “Our pipeline of wholly owned or partnered TRiMTM-enabled candidates now includes three programs in Phase 3 - olpasiran, fazirsiran, and plozasiran. Importantly, our lead wholly owned candidate plozasiran, a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of Apolipoprotein C-III (APOC3), is on schedule to complete its first pivotal Phase 3 study this quarter, with a topline readout soon after.” Olpasiran is a small interfering RNA (siRNA) originally developed by Arrowhead using its proprietary Targeted RNAi Molecule (TRiMTM) platform. It is designed to lower levels of lipoprotein(a) (Lp(a)), a genetically determined risk factor for cardiovascular disease. The primary objective of the Phase 3 OCEAN(a) - Outcomes Trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death, myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a). About Lp(a) Lp(a) is primarily genetically determined1-3 and a presumed independent risk factor for cardiovascular disease (CVD). Although an agreed upon threshold for elevated Lp(a) is not firmly established, approximately 20% of adults have Lp(a) >125 nmol/L (or approximately 50 mg/dL).1 Evidence has emerged from pathophysiological, epidemiologic, and genetic studies on the potential role of elevated Lp(a) in contributing to myocardial infarction, stroke, and peripheral arterial disease.3 About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit , or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit . Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. ________________ Wilson DP, et al. Clin Lipidol. 2019;13(3):374-92. Reyes-Soffer G, et al. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. Tsimikas S, et al. J Am Coll Cardiol. 2018;71(2): 177–192. View source version on businesswire.com: Contacts Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 ir@arrowheadpharma.com Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 britchie@lifesciadvisors.com Media: LifeSci Communications, LLC Kendy Guarinoni, Ph.D. 724-910-9389 kguarinoni@lifescicomms.com Source: Arrowhead Pharmaceuticals, Inc. View this news release online at:

临床3期

2024-04-30

·药明康德

现场 | 汇聚创新·造就机遇: 2024合全药业生态圈沙龙圆满收官

回顾活动精彩瞬间窗外枝头已绽放出无尽生命力的春日时刻，2024年合全药业创新药生态圈沙龙于4月26日在上海圆满收官。创新与合作，是生物医药行业永恒不变的主题；沟通与交流，则是促进合作的根基。本次会议邀请了国际大型制药企业默沙东、美国生物科技企业技术负责人分享了其重磅管线的研发进展与药物开发心得；也邀请了中国生物制药企业技术负责人分享他们如何以创新和速度致胜、脱颖而出走向全球市场的经验；还有合全药业技术负责人所带来的精彩案例及经验分享。通过十位行业技术专家对小分子、多肽分子、寡核苷酸分子领域的不同维度探讨，活动吸引了来自近百家企业的110多位业内同仁参会，使现场观众受益匪浅。傅小勇博士“这是一个业界经验交流与分享的平台”，如药明康德执行副总裁、合全药业负责人傅小勇博士在开场致辞中提到，合全药业生态圈沙龙旨在为全球创新药同仁构建沟通阵地，合全药业也始终致力于与客户共同合作，突破研发瓶颈、提升研发效率、加速创新问世。齐绩博士最近，猎药人网站（drughunter.com）发布2023年度小分子榜单，默沙东的口服PCSK9抑制剂MK-0616入围。MK-0616是一种大环肽，可结合PCSK9并抑制PCSK9与低密度脂蛋白受体（LDLR）相互作用，可通过每日片剂形式给药，针对适应症包括动脉粥样硬化、高胆固醇血症。该分子已在2b期临床试验中显示出高口服利用度和显著降低LDLC的效果。目前，已进入3期临床试验，有望成为首个口服PCSK9抑制剂。默沙东高级首席科学家、高级总监齐绩博士以“The Largest Small Molecule: How Chemistry Enabled the Discovery and Development of PCSK9 Inhibitor MK-0616”为主题，分享了MK-0616研发过程中的化学新技术应用、工艺放大等经验，强调了技术创新化、研发策略差异化在新药研发过程中的重要性。Andrew Clausen博士神经病学涵盖了从神经退行性疾病（如帕金森病、阿尔茨海默病）到癫痫、抑郁症、偏头疼，乃至众多罕见疾病的广泛领域，人类世界持续的精神健康危机，让有限的治疗选择局面正逐渐被打破。Cerevel Therapeutics一直致力于解开大脑的奥秘，以治疗神经科学疾病。近期，该公司公布其关键3期临床试验TEMPO-3的积极顶线结果，该试验达到主要终点，证明其用于治疗帕金森病的多巴胺D1/D5选择性部分激动剂——Tavapadon作为左旋多巴（LD）的辅助治疗，能有效改善帕金森病患者的运动症状。这些试验结果将支持该药物相关监管申请。该公司高级副总裁、Technical Operation负责人Andrew Clausen博士在生态圈沙龙中，以“Nimble Process Development of a Dopamine D1/D5 Receptor Agonist: Current State and Future Opportunities”为主题，介绍了Tavapadon的应用前景及未来机遇。此外，讲者通过展示Tavapadon在合成与开发过程中的技术挑战与解决方案，强调了精准且高效的创新化学技术的应用对药物开发的助力作用。佘劲博士寡核苷酸药物发展之势难以阻挡，维亚臻生物在针对心血管及代谢疾病领域的siRNA药物研发有着其独到策略。作为中国小核酸药物行业的代表企业之一，近期，其1类新药VSA001注射液已顺利完成中国家族性乳糜微粒血症综合征（FCS）3期临床试验超过36例全部患者入组；VSA003注射液也已被国家药品监督管理局药品审评中心（CDE）纳入突破性治疗药物品种名单。维亚臻生物首席技术官、CMC执行副总裁佘劲博士以“Opportunities & Challenges of Oligonucleotide Therapies and Visirna Approach”为主题，基于其在药物生产和工艺开发等领域的深厚技术积累和深入理解，分享了寡核苷酸药物CMC工艺研发的关键点。此外，佘博士还就维亚臻的产品开发策略，该公司潜力分子的开发进展，及未来蓝图进行了全面分享。吴振平博士随着中国创新药生态不断完善，国际间创新药企业的交流合作不断增多，越来越多来自中国生物制药企业的明星分子亮相国际会议，一些生物技术公司（Biotech）开始升级成为生物制药公司（BioPharma），走向全球市场。和黄医药正是这样一家处于商业化阶段的创新型生物医药公司，旨在成为发现、开发及商业化治疗癌症及免疫性疾病靶向治疗及免疫疗法的全球领导者。和黄医药执行副总裁、药物科学与生产负责人吴振平博士本次以“Roles of CMC in Building a BioPharma Company in China”为主题，重点从：加速药物开发、推动全球化、及控制成本，三个角度深度剖析了CMC的助力作用，强调了在创新药研发和生物制药公司持续发展过程中，CMC的重要贡献。龚豫川博士百济神州自主研发的第二代BTK抑制剂百悦泽®（泽布替尼）作为首款在美国上市的中国新药在2023年全球销售额达到13亿美元，成为中国首个突破十亿美元的“重磅炸弹”级创新产品，可谓中国新药“出海”的典范之一。而一款产品的成功离不开药物研发各环节的努力，百济神州副总裁、小分子CMC负责人龚豫川博士以“Effective CMC Development of Oral Solid Drug Product”为主题，分享了该公司的CMC策略。演讲伊始，龚博士首先强调：“CMC是用数据驱动的过程，将分子转化为临床可用的药物产品；也是一个持续优化的过程，从而为产品实现商业化提供几乎完美的方案。”此外，他还从原料药、制剂、分析和生产四个角度，具体介绍了百济神州的实践经验，从而不断助力该公司管线中的药物分子向临床开发、向商业化推进。陈金玲博士药明康德高级副总裁、制剂研发和生产业务部负责人陈金玲博士以“Accelerated Pharmaceutical Development: Speed and Complexity, a New Norm for Our Industry”为演讲主题，基于行业趋势，以案例引入，分享了合全药业一体化CMC平台应对PROTACs、寡核苷酸等药物开发的经验，引发热烈讨论。CMC圆桌讨论环节圆桌讨论环节，烨辉医药董事长兼首席执行官、创始人华烨博士、Cerevel Therapeutics首席科学馆John Renger博士、默沙东Discovery Process Chemistry总监Dani Schultz博士，协同百济神州龚豫川博士，展开讨论。他们围绕：药物开发速度对不同规模类型公司的意义、M&A/授权交易/联合开发多种模式下的机会与挑战、CMC开发的具体风险与解决、起始物料的选择、创新技术在CMC中的应用等角度进行深入讨论，给在场观众以启发。该环节由药明康德高级副总裁、小分子原料药后期和商业化项目业务部负责人陈珂博士主持。华烨博士烨辉医药董事长兼首席执行官、创始人John Renger博士Cerevel Therapeutics首席科学官Dani Schultz博士默沙东Discovery Process Chemistry总监陈珂博士药明康德高级副总裁、小分子原料药后期及商业化部负责人本次合全药业生态圈沙龙在陈金玲博士的闭幕致词中圆满收官。正如同本次会议主题“汇聚创新，造就机遇”，我们期待越来越多的创新药领域技术人员能汇集于生态圈沙龙，通过沟通迸发创新的火花，通过创新使行业跃步向前，通过携手让破解困局成为可能。行业的交流与合作永远是进行时，我们期待下一个春暖花开之际，与您再度相约合全药业生态圈沙龙，道一道新药研发故事。

临床3期临床2期

2024-04-29

·BioSpace

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024 Type: Fireside Chat Presentation Date/Time: May 14, 2024, 9:30 a.m. EDT BofA Securities 2024 Healthcare Conference – May 13-16, 2024 Type: Fireside Chat Presentation Date/Time: May 16, 2024, 8:40 a.m. PDT TIDES USA 2024 – May 14-17, 2024 Title: Preclinical Pro ARO-SOD1, an siRNA Therapy for SOD1-ALS Date/Time: May 16, 2024, 3:00 p.m. EDT Presenter: Christine Esau, Ph.D. Session: Oligonucleotide Chemistry, Mechanisms and Preclinical Title: Novel TRiMTM Platform for Delivery of RNAi Therapeutics to Adipose Tissue Date/Time: May 17, 2024, 9:00 a.m. EDT Presenter: Tao Pei, Ph.D. Session: Delivery of Macromolecules American Thoracic Society (ATS) 2024 International Conference – May 17-22, 2024 Title: A First-in-Human Study of ARO-RAGE, a Novel Inhaled RNA-Interference Therapy for Asthma Date/Time: May 19, 2024, 11:30 a.m. PDT Type: Late-Breaking Poster Title: A lung-targeted therapeutic siRNA against highly conserved viral M1 mRNAs effectively limits highly pathogenic influenza A infection in mice Date/Time: May 20, 2024, 11:30 a.m. PDT Type: Poster Title: Lung-targeted RNAi molecules silence human TSLP expression in PCLS cultures and humanized mice and suppress pulmonary allergic inflammation Date/Time: May 20, 2024, 11:30 a.m. PDT Type: Poster 37th International Conference on Antiviral Research (ICAR2024) – May 20-24, 2024 Title: Liver-targeted therapeutic siRNAs against highly conserved yellow fever virus genomic sequences effectively limit infection and mortality in a hamster model Date/Time: May 22, 2024, 10:45 a.m. AEST Presenter: Justin Julander, Ph.D. Session: Lipid Lowering via Novel Pathways European Atherosclerosis Society (EAS) 92nd Congress – May 26-29, 2024 Title: PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS Date/Time: May 28, 2024, 12:04 p.m. CEST Presenter: Christie M Ballantyne, M.D. Session: New Therapeutics Title: PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS Date/Time: May 28, 2024, 2:49 p.m. CEST Presenter: Daniel Gaudet, M.D., Ph.D. Session: SaaG Session: The Enigmas of TG-rich Lipoproteins Title: ZODASIRAN SILENCES HEPATIC ANGPTL3 LEADING TO DEEP AND DURABLE REDUCTIONS IN ATHEROGENIC LIPIDS AND LIPOPROTEINS IN MIXED DYSLIPIDEMIA PATIENTS: FINAL RESULTS FROM ARCHES-2, DOUBLE-BLIND PERIOD Date/Time: May 29, 2024, 11:30 a.m. CEST Presenter: Robert Rosenson, M.D. Session: Late Breaker Session 2: New Therapeutic Agents 2024 National Lipid Association (NLA) Scientific Sessions – May 30 – June 2, 2024 Title: ENCORE - PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS Date/Time: May 31, 2024, 2:30 p.m. PDT Presenter: Christie M Ballantyne, M.D. Session: Poster Title: ENCORE - PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS Date/Time: June 1, 2024, 12:20 p.m. PDT Presenter: Christie M Ballantyne, M.D. Session: Late Breaker Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit , or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit . Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.

siRNA寡核苷酸

100 项与 Plozasiran 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
高甘油三酯血症	临床3期	-	Arrowhead Pharmaceuticals, Inc. 更多
家族性乳糜微粒血症综合征	临床3期	墨西哥更多	Arrowhead Pharmaceuticals, Inc. 更多
血脂障碍	临床2期	荷兰更多	Arrowhead Pharmaceuticals, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04720534 (SHASTA-2, Corporate Publications) 人工标引	临床2期	高甘油三酯血症	226	Plozasiran 10 mg	鹹觸淵選夢製艱構糧網(範壓範衊製醖淵顧憲衊) = 鏇積餘簾遞獵網選艱廠繭鏇餘齋壓窪鏇簾網窪 (網廠願願獵鏇淵艱淵構 ) 更多	积极	2023-11-13
				Plozasiran 25 mg	鹹觸淵選夢製艱構糧網(範壓範衊製醖淵顧憲衊) = 壓淵築積窪網鬱醖築鹹繭鏇餘齋壓窪鏇簾網窪 (網廠願願獵鏇淵艱淵構 ) 更多
NCT04998201 (MUIR, AHA2023) 人工标引	临床2期	血脂障碍	353	ARO-APOC3 10mg Q12W	壓顧憲範簾鹽膚齋網齋(窪選餘齋製餘憲鹹艱鑰) = 蓋蓋鏇顧齋觸簾糧鑰觸餘糧積鬱積遞觸築鹽積 (顧膚醖廠鹽糧願願艱壓, 3.55) 更多	积极	2023-11-06
				ARO-APOC3 25mg Q12W	壓顧憲範簾鹽膚齋網齋(窪選餘齋製餘憲鹹艱鑰) = 艱窪餘網網鏇獵衊遞製餘糧積鬱積遞觸築鹽積 (顧膚醖廠鹽糧願願艱壓, 3.51) 更多